
Sign up to save your podcasts
Or


In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Cathleen McCabe, MD, about the ASCRS Foundation and role models in ophthalmology; plus, the latest news in eye care.
• Welcome to the Eyeluminaries podcast :05 • Review of episode 25 :46 • Bausch + Lomb acquires Trukera Medical 1:32 • CMS proposes cutting physician payments for fifth straight year 4:09 • FDA clears Alcon's Unity cataract system, Unity vitreoretinal cataract system 7:40 • FDA approves Eylea biosimilar FYB203/Ahzantive 11:07 • Intro of Cathleen McCabe, MD 13:07 • American Society of Cataract and Refractive Surgery (ASCRS) has become an important organization to advocate, educate and organize doctors and their practices. As future president of the organization, what vision do you have for the organization? 15:26 • In reference to your practice, what challenges are you facing and how do you overcome them? 18:59 • Besides the two of us, who do you admire in ophthalmology? 23:37 • Tell us about your work, what you do and how you do it. 27:21 • Preview of episode 27 33:30 • Thanks 34:58
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL.
We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.
Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. McCabe reports no relevant financial disclosures.
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Octane OTF with Euan Thomson, PhD, Barry Kuppermann, MD, Jeffry Weinhuff, Ehsan Sadri, MD, FACS, and a special announcement from Rich Small.
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Barry Kuppermann, MD, PhD, is the Roger F. Steinert professor, chair of the department of ophthalmology and director of the Gavin Herbert Eye Institute at the University of California, Irvine. He also holds a joint appointment with the department of biomedical engineering at UC Irvine.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Ehsan Sadri, MD, FACS, FAAO, is board-certified, fellowship-trained in treating LASIK, cataract and glaucoma surgeries with locations to serve patients in Newport Beach, Santa Ana and Orange. He is also CEO and founder of Visionary Eye Institute and general partner and co-founder of Visionary Ventures Fund (Visionaryvc.com).
Rich Small is CEO and member of the board of directors for Neurotech.
Euan Thomson, PhD, is the president of ophthalmic devices and head of digital business unit at Carl Zeiss Meditec Inc.
Jeffry Weinhuff is the chief investment officer and managing partner of Visionary Ventures Fund, a later-stage venture fund focused on investing in drugs and devices for the eye.
We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.
Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Sadri is the CEO and founder of Visionary Eye Institute and general partner and co-founder of Visionary Ventures Fund. Weinhff is the managing partner of Visionary Ventures Fund. Small is chief executive officer and member of the board of directors for Neurotech. Thomson is the president of ophthalmic devices and head of digital business unit at Carl Zeiss Meditec Inc. Weinhuff is the managing partner of Visionary Ventures Fund.
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss leadership in eye care with guest Jack T. Holladay, MD, MSEE, FACS.
Brought to you by Johns Hopkins University. • Welcome to the Eyeluminaries podcast :21 • Review of episode 23 1:19 • Blog by John A. Hovanesian, MD, FACS 3:10 • Merck to acquire EyeBio 4:14 • FDA approves aflibercept biosimilars Yesafili, Opuviz 6:26 • Aurion Biotech completes enrollment in phase 1/2 corneal edema cell therapy trial 8:43 • Intro of Jack Holladay, MD, MSEE 11:10 • How did you develop a passion for optics? Did you know it was going to be your future? 13:50 • Holladay's life-threatening situation 16:21 • Holladay's experience teaching residents 23:50 • Holladay's optics strategy for improving his golf game 28:33 • Preview of episode 25 32:25 • Feedback, questions and guest suggestions at [email protected] 32:45
Jack T. Holladay, MD, MSEE, FACS, is a clinical professor of ophthalmology at Baylor College of Medicine and retired from clinical ophthalmic practice. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus.
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Terry Kim, MD, and Stephen Lane about their careers and transitions at Alcon.
Brought to you by Johns Hopkins University.
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Terry Kim, MD, is a professor of ophthalmology at Duke University Eye Center.
Stephen Lane is a founding partner of Associated Eye Care.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.
Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news in eye care and chat with Wiley A. Chambers, MD, about his career in the FDA and his plans for retirement.
Brought to you by Johns Hopkins University
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Wiley A. Chambers, MD, is a clinical professor of ophthalmology and adjunct assistant professor of computer medicine at The George Washington University and owner of Ocular Advisors, LLC.
We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.
Disclosures: Chambers is the owner of Ocular Advisors, LLC. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.
Quick episode summary
John A. Hovanesian, MD, FACS, and Jim Mazzo sit down with guests Eric D. Donnenfeld, MD, Calvin C. Roberts, MD, Mark L. Baum and Jeannette Bankes to discuss private equity, industry breakthroughs and more.
· If you could change anything in the ophthalmic industry, what would it be? 42:53
· How excited are you about robotics? 44:06
· Tell us about your promotion 44:52
· How can we develop a more diverse leadership in ophthalmology? 45:31
Jeannette Bankes is the president and general manager of global surgical franchises for Alcon.
Mark L. Baum is the founder, chairman of the board and chief executive officer of Harrow.
Eric D. Donnenfeld, MD, is a cornea, laser cataract and refractive surgeon for OCLI Vision.
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Calvin C. Roberts, MD, is a program manager for health science futures at ARPA-H.
We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.
Disclosures: Bankes is the president and general manager of global surgical franchises for Alcon. Baum is the founder, chairman of the board and chief executive officer of Harrow. Donnenfeld reports consulting widely across the ophthalmic industry with relevant disclosures in this episode as a consultant with Alcon, Bausch + Lomb, LensGen, Ocular Therapeutix and Omeros. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision. Roberts is program manager for health science futures at ARPA-H.
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Vance Thompson, MD, Adrienne Graves, PhD, Sean Ianchulev, MD, and Kristen Harmon Igenito, live from AAO Eyecelerator.
· Who or what inspires you? 45:58
Adrienne Graves, PhD, serves as an independent director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix and serves as director on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund.
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health.
Kristen Harmon Ingenito has more than a decade of experience in the ophthalmic industry, with nine of those years analyzing data and reporting for Market Scope. Kristen's industry experience began in 2005 at Market Scope, where she served in many roles, including editing, analysis, sales, and marketing. She then joined an ophthalmic patient education software company, where she worked closely with physicians to help drive value in all aspects of their practices, while also training incoming executives on the business of eye care. She returned to Market Scope with added experience to help expand the company's portfolio of products and services. Source: Market Scope
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Vance Thompson, MD, is a board-certified ophthalmologist who specializes in refractive surgery including laser vision correction, implant vision correction and advanced cataract surgery and is the director of refractive surgery at Vance Thompson Vision.
We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.
Disclosures: Graves serves as an independent director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix and serves as director on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund. Hovanesian consults widely in the ophthalmic field. Ianchulev is the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. Ingenito develops products and provides services to Market Scope. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision.
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Peter Slack, Greg Kunst, Rich Small and Uday Devgan, MD, FACS, FRCS, live from OSN New York.
· Give us a good Jim Mazzo story 34:38
Uday Devgan, MD, FACS, FRCS(Glasg), is Healio|OSN section editor for Ocular Surgery News. He is in private practice, specializing in cataract and refractive surgery, at Devgan Eye Surgery in Los Angeles and a full partner at Specialty Surgical Center in Beverly Hills, California. He has previously served as full clinical Professor of Ophthalmology at the Jules Stein Eye Institute at the UCLA School of Medicine as well as Chief of Ophthalmology at Olive View-UCLA Medical Center and has been actively involved in resident surgical teaching for over two decades. He owns and operates CataractCoach.com.
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Greg Kunst is president, chief executive officer and board member at Aurion Biotech. He is focused in areas such as R&D, clinical development, corporate development, strategy, marketing, commercial, business development, market access and medical affairs with extensive knowledge of global health care markets (North America, Latin America, Europe, Asia), global commercialization and market development, upstream and downstream marketing, market access, and medical affairs for medical device, drug delivery systems, diagnostic systems, biotechnology, cell therapies, gene therapies, biologics, and pharmaceutical products.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Peter N. Slack is president and chief executive officer of The Wyanoke Group. Peter is past-Chairman and a current member of the Board of Trustees for the Center for Family Services, a nonprofit human services agency. Other professional titles and memberships have included Board of Directors of the International Association of Association Management Companies and Board of Directors of the American Medical Publishers Association. In addition, Peter is President of the Broadway Theatre of Pitman in Pitman, NJ. Disclosure: The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast.
Rich Small is chief executive officer and member of the board of directors for Neurotech. He originally joined Neurotech in July 2007 as the company's chief financial officer. He has in excess of 30 years of both private and public life sciences experience and more than 40 years of overall financial and operational management. Previously Rich served as Senior Vice President and Chief Financial Officer of Point Therapeutics, a publicly traded biotechnology company focused in developing treatments for various cancers.
We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.
Disclosures: Devgan owns and operates CataractCoach.com. Hovanesian consults widely in the ophthalmic field. Kunst is president, chief executive officer and board member at Aurion Biotech. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Slack is president and chief executive officer of The Wyanoke Group. Small is chief executive officer and member of the board of directors for Neurotech. The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast.
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Julia Haller, MD, about the latest developments in retina, residency training and more.
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Julia Haller, MD, is Ophthalmologist-in-Chief and William Tasman, MD Endowed Chair at Wills Eye Hospital and Professor and Chair of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, PA.
We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.
Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Haller reports being on the board of directors at Bristol Myers Squibb, Opthea and Outlook Therapeutics. She is consultant to Aura Biosciences, Bionic Sight, Lowy Medical Research Institute and Regeneron.
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at OCTANe OTS with Mark Leahey, Brent Saunders, Yari Mitchell and Robert Dempsey, discussing their experiences and influence across the ophthalmic space.
· Welcome to the Eyeluminaries podcast :01
· Review of episode 16 with Stephen McLeod, MD :28
· Preview of episode 17, live at Octane OTS 1:00
· Introduce Mark Leahey, president & CEO for the Medical Device Manufacturers Association 1:23
· Challenges in medical device 2:19
· Is it possible for the government to reduce regulation of medical devices while still protecting patients? 4:32
· What is MDMA doing for sustainability? 6:50
· What is one issue that device manufacturers need to implement? 9:04
· Introduce Brent Saunders, Chairman and CEO of Bausch + Lomb 12:23
· What's different about Bausch + Lomb today that wasn't around when you first worked for the company? 13:27
· Tell us about other products at Bausch + Lomb. 19:22
· Introducing Yari Mitchell, the president of Y Factor Consulting, Inc. 23:31
· What have been the most important changes in the ophthalmic industry over the past couple of years? 24:58
· What advice would you give to an early-career person? 26:15
· Favorite memories of Jim Mazzo 29:14
· Introducing Robert Dempsey, CEO and President of AsclepiX Therapeutics 32:10
· What was it like to leap from medical sciences to a leadership position? 33:22
· Managing a pipeline that includes both retinal and cornea treatments 35:05
· How do you establish yourself as a competitor in age-related macular degeneration research in a mature and crowded market with limited resources? 36:10
· Creating a retinal treatment delivered via the suprachoroidal route 37:28
· The Holland Foundation For Sight Restoration seeking to spread access to eye care for patients and the importance of giving back 38:27
· Feedback, questions and guest suggestions at [email protected] 44:00
· Thanks for listening 44:19
Robert Dempsey is the CEO and president of AsclepiX Therapeutics.
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Mark Leahey is the president and CEO of the Medical Device Manufacturers Association.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Yari Mitchell is the president of Y Factor Consulting, Inc.
Brent Saunders is the chairman and CEO of Bausch + Lomb.
We'd love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.
Disclosures: Dempsey is the president and CEO of AsclepiX Therapeutics. Hovanesian consults widely in the ophthalmic field. Leahey is the president & CEO for the Medical Device Manufacturers Association. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Mitchell is the chief business development officer at AcuFocus and the president of Y Factor Consulting, Inc. Saunders is the chairman and CEO of Bausch + Lomb.
From the publisher's feed

2,445 Listeners

121 Listeners

9 Listeners

31 Listeners

30 Listeners

5 Listeners

15 Listeners

5 Listeners

13 Listeners

50 Listeners

6 Listeners